Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Isofol Medical AB ( (SE:ISOFOL) ) has shared an announcement.
Isofol Medical AB announced the launch of a new Advisory Board during the ASCO 2025 conference in Chicago, a leading oncology event. The board, comprising prominent global cancer experts, will support Isofol’s global development program and preparations for regulatory meetings in the U.S. and Japan, potentially enhancing the company’s strategic positioning in the oncology field.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. Its primary product, arfolitixorin, is a drug candidate aimed at enhancing the effectiveness of first-line standard treatments for solid tumors, particularly in colorectal cancer. The company is currently conducting a phase Ib/II study to optimize the drug’s dosage regimen.
Average Trading Volume: 545,523
Current Market Cap: SEK192M
Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.